RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML

Author:

Brown Anna L.123ORCID,Arts Peer12ORCID,Carmichael Catherine L.4,Babic Milena12,Dobbins Julia12,Chong Chan-Eng1,Schreiber Andreas W.56ORCID,Feng Jinghua26,Phillips Kerry7,Wang Paul P. S.6ORCID,Ha Thuong12,Homan Claire C.12,King-Smith Sarah L.12,Rawlings Lesley1,Vakulin Cassandra1,Dubowsky Andrew1,Burdett Jessica1,Moore Sarah1,McKavanagh Grace1,Henry Denae1,Wells Amanda1,Mercorella Belinda1,Nicola Mario1,Suttle Jeffrey1,Wilkins Ella8,Li Xiao-Chun2,Michaud Joelle8,Brautigan Peter12,Cannon Ping8,Altree Meryl7,Jaensch Louise7,Fine Miriam7,Butcher Carolyn29,D’Andrea Richard J.2,Lewis Ian D.410,Hiwase Devendra K.3911,Papaemmanuil Elli12,Horwitz Marshall S.13ORCID,Natsoulis Georges14,Rienhoff Hugh Y.14,Patton Nigel15,Mapp Sally16,Susman Rachel17,Morgan Susan18,Cooney Julian19,Currie Mark20,Popat Uday21ORCID,Bochtler Tilmann22ORCID,Izraeli Shai2324ORCID,Bradstock Kenneth25,Godley Lucy A.26,Krämer Alwin22ORCID,Fröhling Stefan2728,Wei Andrew H.29,Forsyth Cecily30ORCID,Mar Fan Helen17,Poplawski Nicola K.731,Hahn Christopher N.123ORCID,Scott Hamish S.1236ORCID

Affiliation:

1. Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia;

2. Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia;

3. School of Medicine, University of Adelaide, Adelaide, SA, Australia;

4. Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia;

5. School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia;

6. Australian Cancer Research Foundation (ACRF) Cancer Genomics Facility, Centre for Cancer Biology, SA Pathology, Adelaide, SA, Australia;

7. Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, SA, Australia;

8. Department of Molecular Medicine, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia;

9. Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia;

10. Department of Haematology, SA Pathology, Adelaide, SA, Australia;

11. Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia;

12. Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY;

13. Department of Pathology, University of Washington, Seattle, WA;

14. Imago Biosciences, Inc, San Francisco, CA;

15. Department of Haematology, Auckland City Hospital, Auckland, New Zealand;

16. Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia;

17. Genetic Health Queensland, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia;

18. Department of Haematology, Alfred Hospital, Melbourne, VIC, Australia;

19. Department of Haematology, Fiona Stanley Hospital, Murdoch, WA, Australia;

20. LewisGale Medical Center, Salem, VA;

21. The University of Texas MD Anderson Cancer Center, Houston, TX;

22. Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, University of Heidelberg and German Cancer Research Center, Heidelberg, Germany;

23. Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel;

24. Pediatric Hemato-Oncology, Schneider Children's Medical Center, Petach Tiqva, Israel;

25. Haematology Department, Westmead Hospital, Westmead, NSW, Australia;

26. Section of Hematology/Oncology, Department of Medicine and Center for Clinical Cancer Genetics, and The University of Chicago Comprehensive Cancer Center, The University of Chicago, Chicago, IL;

27. National Center for Tumor Diseases Heidelberg, German Cancer Research Center, Heidelberg University Hospital, Heidelberg, Germany;

28. German Cancer Consortium, Heidelberg, Germany;

29. The Alfred Hospital, Monash University, Melbourne, VIC, Australia;

30. Jarrett St Specialist Centre, North Gosford, NSW, Australia; and

31. Discipline of Paediatrics, Faculty of Health Sciences, School of Medicine, University of Adelaide, Adelaide, SA, Australia

Abstract

Abstract First reported in 1999, germline runt-related transcription factor 1 (RUNX1) mutations are a well-established cause of familial platelet disorder with predisposition to myeloid malignancy (FPD-MM). We present the clinical phenotypes and genetic mutations detected in 10 novel RUNX1-mutated FPD-MM families. Genomic analyses on these families detected 2 partial gene deletions, 3 novel mutations, and 5 recurrent mutations as the germline RUNX1 alterations leading to FPD-MM. Combining genomic data from the families reported herein with aggregated published data sets resulted in 130 germline RUNX1 families, which allowed us to investigate whether specific germline mutation characteristics (type, location) could explain the large phenotypic heterogeneity between patients with familial platelet disorder and different HMs. Comparing the somatic mutational signatures between the available familial (n = 35) and published sporadic (n = 137) RUNX1-mutated AML patients showed enrichment for somatic mutations affecting the second RUNX1 allele and GATA2. Conversely, we observed a decreased number of somatic mutations affecting NRAS, SRSF2, and DNMT3A and the collective genes associated with CHIP and epigenetic regulation. This is the largest aggregation and analysis of germline RUNX1 mutations performed to date, providing a unique opportunity to examine the factors underlying phenotypic differences and disease progression from FPD to MM.

Publisher

American Society of Hematology

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3